

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1011)**

## **Appointment of Non-executive Director**

The board of directors (the "**Board**") of China NT Pharma Group Company Limited (the "**Company**") is pleased to announce that Mr. Lou Yongbin ("**Mr. Lou**") has been appointed as a non-executive director of the Company (the "**Non-executive Director**") with effect from 13 April 2026 (the "**Effective Date**") .

Pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), the biographical details of Mr. Lou are set out below:

Mr. Lou, aged 46, graduated from Zhejiang Technician Institute of Mechanical and Electrical Engineering and has over 20 years of experience in entrepreneurship, enterprise management and investment. He served as the manager of Yiwu Junbin Ribbon Factory from November 2005 to September 2012; subsequently as the director and legal representative of Zhejiang Guihui Trading Co., Ltd. from April 2012 to April 2016; and has been serving as the director and legal representative of Yiwu Panshi Real Estate Co., Ltd. since May 2022. Mr. Lou has been serving as the chairman and legal representative of Zhejiang Kangyuan Medical Devices Co., Ltd. since June 2024.

Save as disclosed above, Mr. Lou has not held any directorships in any public companies whose securities are listed on any securities market in Hong Kong or overseas in the past three years, nor has he held any other positions in the Company or any of its subsidiaries.

As at the date of this announcement, Mr. Lou holds 61,073,627 Shares of the Company, representing approximately 6.43% of the total issued shares of the Company. Mr. Lou Yongjun, the elder brother of Mr. Lou, holds 47,328,267 Shares of the Company, representing approximately 4.99% of the total issued shares of the Company. Save as disclosed above, Mr. Lou does not have any other interests in the Shares of the Company (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)).

Save as disclosed above, Mr. Lou does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company, or their respective associates (as defined in the Listing Rules), and there is no arrangement or agreement for voting or acting in concert between Mr. Lou and Mr. Lou Yongjun other than their fraternal relationship.

Mr. Lou has entered into a letter of appointment with the Company, pursuant to which his appointment shall take effect from the effective date for a term of three years, and is subject to

retirement and re-election at the forthcoming annual general meeting of the Company. Mr. Lou will not receive any director's remuneration for his position as a Non-executive Director.

The Board is of the view that Mr. Lou possesses appropriate professional knowledge and industry experience and is suitable to act as a Non-executive Director. The Nomination Committee has reviewed and confirmed that the appointment of Mr. Lou is in compliance with the board diversity policy, and his professional expertise will facilitate the integration of the Group's newly acquired medical technology assets and the strategic transformation towards an AI healthcare platform.

Save as disclosed above, there is no other information in respect of the appointment of Mr. Lou that needs to be disclosed pursuant to Rule 13.51(2) of the Listing Rules, and there are no other matters that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

The Board extends a warm welcome to Mr. Lou on his appointment.

By order of the Board  
**China NT Pharma Group Company Limited**  
*Chairman*  
**NG Tit**

Hong Kong, 13 April 2026

*As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Ng Anna Ching Mei; the non-executive Directors are Dr. Qian Wei and Ms. Chin Yu; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Ng Ming Kwan and Dr. Zhao Yubiao.*